Clinical trials: Omeprazole
Peptic Ulcer Disease
Study Comparing Esomeprazole and ASA Combined Together as One Capsule Versus These Medications Taken Separately
The purpose of this study is to investigate whether a fixed dose combination (FDC) capsule of esomeprazole 20 mg and acetylsalicylic acid (ASA) 81 mg has equivalent therapeutic efficacy compared to each of 2 free combinations of…
- Trial name
- NCT01015729
- Testing
- Esomeprazole/ASA Fixed Combination, Esomeprazole, ASA
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (Anagrelide Hydrochloride) in Healthy Adult Participants
This Phase 1, open-label, single-sequence, non-randomized, multiple-dose, crossover pharmacokinetic study is a single site study in the United States and will be conducted to assess the effect of a CYP1A2 inducer (omeprazole 40…
- Trial name
- NCT03866434
- Testing
- SPD422, Omeprazole
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Shire
Healthy Volunteers
Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)
The purpose of this study is to investigate the acid-inhibitory effect of multiple oral doses of Vonoprazan (TAK-438) and the relative effect of vonoprazan versus two controls (esomeprazole and rabeprazole sodium) in healthy…
- Trial name
- NCT02037477
- Testing
- Vonoprazan, Esomeprazole, Rabeprazole sodium
- Where
- Japan
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Takeda
GERD
A Study to Compare PK and Safety of CKD-381 and D026 in Healthy Male Subjects
A Study to compare pharmacokinetics and safety of CKD-381 and D026 in healthy male subjects
- Trial name
- NCT03444402
- Testing
- CKD-381(formulation I), CKD-381(formulation II), D026(Nexium 40mg)
- Where
- South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy
Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects
Primary objective: Assess the effects of clopidogrel (300 mg loading dose followed by 4 days 75 mg/day) on Adenosine diphosphate (ADP)-induced platelet aggregation when given concomitantly with omeprazole 80 mg/day compared to…
- Trial name
- NCT01129375
- Testing
- clopidogrel, omeprazole
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Sanofi
Barrett's Esophagus
Barrett's Esophagus - 315 - 3 Way Cross-Over
This study looks the intragastric and intraesophageal pH in patients with documented Barrett's esophagus whilst taking esomeprazole 40mg twice daily, esomeprazole 40mg three times daily, esomeprazole 20 mg three times daily.
- Trial name
- NCT00637559
- Testing
- Esomeprazole Magnesium
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Healthy Volunteers
A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants
The primary purpose of this study is to assess the effects of rifampin on the PK of brensocatib in Part 1 of the study and to assess the effects of esomeprazole on the PK of brensocatib in Part 2 of the study.
- Trial name
- NCT05826574
- Testing
- Brensocatib, Rifampin, Esomeprazole
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Insmed Incorporated
Chemotherapy-induced Nausea and Vomiting
An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects
The objective of this Open Label Study is to evaluate effects of Rolapitant IV solution, and its metabolite, on the pharmacokinetics (PK) of the P-gp substrate (digoxin), the BCRP substrate (sulfasalazine), and multiple…
- Trial name
- NCT02434861
- Testing
- Rolapitant, Digoxin, Sulfasalazine
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Tesaro, Inc.
Leukemia, Myeloid, Acute
A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients
This is a 2-part, open-label, interventional study conducted in approximately 42 subjects with AML harboring an IDH2 mutation. The overall study is a 3-arm investigation of the PK effects of enasidenib at steady state on the…
- Trial name
- NCT03720366
- Testing
- enasidenib, Arm 1 probes, Arm 2 Probes
- Where
- 10 sites in Australia, South Korea
- Volunteers
- 40 people
- Sponsor
- Celgene
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Drug-Drug Interactions of JMKX003142 in Healthy Participants
This is a single-center, non-randomized, open-label, self-controlled, Phase I clinical trial to evaluate the drug-drug interactions (DDI) of JMKX003142 tablets in healthy adult participants.
- Trial name
- NCT07565441
- Testing
- JMKX003142 tablets, Fluconazole Capsules, Cocktail Substrates (Midazolam Oral Solution, Rosuvastatin Calcium Tablets, and Digoxin Tablets)
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Jemincare
Dose Finding Study
Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Western Male Subjects, Preliminary Food Effect Analysis, and an Ethnic Comparison With Japanese Subjects
The primary purpose of this study was to evaluate the safety, tolerability, and pharmacokinetics of TAK-438 following single or multiple doses of TAK-438 in healthy Western men, to investigate the effect of food on the…
- Trial name
- NCT02141698
- Testing
- TAK-438, Esomeprazole
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Takeda
Relapsing-Remitting Multiple Sclerosis
An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis
The primary objective of the study is to assess the immunogenicity of Daclizumab High Yield Process (DAC HYP) 150 mg administered every 4 weeks by subcutaneous (SC) injection using the pre-filled syringe (PFS) in participants…
- Trial name
- OBSERVE (NCT01462318)
- Testing
- Midazolam, Caffeine, S-warfarin
- Where
- 19 sites in United States, Czechia and 2 more
- Volunteers
- 133 people
- Sponsor
- Biogen
Heartburn, Upper Abdominal Pain
A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients
This study looks at controlling intragastric pH following administration of esomeprazole 40 mg, lansoprazole 30 mg and pantoprazole 40 mg taken orally, once daily in patients taking either non-selective or cyclooxygenase-2…
- Conditions
- Heartburn, Upper Abdominal Pain, Nausea, Acid Regurgitation
- Trial name
- NCT00625274
- Testing
- Esomeprazole, Lansoprazole, Pantoprazole
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Stress Ulcer Prophylaxis
Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients
The efficacy of esomeprazole will be compared versus cimetidine (a drug that previously demonstrated prevention of bleeding events) during treatment period in proportion of patients for the prevention of upper GI bleeding.
- Trial name
- SUP (NCT02157376)
- Testing
- Esomeprazole, Cimetidine
- Where
- 15 sites in China
- Volunteers
- 343 people
- Sponsor
- AstraZeneca
Healthy
Comparison of Prilosec Over-the-counter (OTC)® Versus Prevacid® for Gastric Acid Suppression
The objective of this study is to compare Prilosec OTC® to Prevacid® for gastric acid suppression.
- Trial name
- NCT00903448
- Testing
- Prilosec OTC (omeprazole-magnesium), Prevacid
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Procter and Gamble
Gastroesophageal Reflux
Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)
The purpose of this study is to determine the effect of vonoprazan compared to esomeprazole for preventing heartburn symptoms over a 4-week treatment period in participants who have a partial response to treatment with…
- Trial name
- NCT02743949
- Testing
- Vonoprazan, Esomeprazole
- Where
- 39 sites in Belgium, Bulgaria and 4 more
- Volunteers
- 256 people
- Sponsor
- Takeda
Healthy Subjects
Assessment of the Effect of Omeprazole on Vicagrel in Healthy Subjects
The primary objective of the study is to evaluate the effects of omeprazole on the PK and PD of a single dose of vicagrel in healthy subjects.
- Trial name
- NCT05651074
- Testing
- Vicagrel and omeprazole
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Healthy
A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)
The goal of the study is to learn what happens to different doses and forms of Embibatinib in a healthy person's body over time.
- Trial name
- NCT07838987
- Testing
- Embibatinib, Rabeprazole, Midazolam
- Where
- United States
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Chest Pain, Gastroesophageal Reflux
Chest Pain Pilot Study
The purpose of this study is to compare the efficacy of Nexium® with placebo in relief of acid related pain or discomfort in the chest.
- Trial name
- NCT00251901
- Testing
- Esomeprazole
- Where
- 80 sites in Canada, Denmark and 4 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Healthy
A Study to Investigate the Effect of Single and Repeated Oral Doses of ACT-539313 on What the Body Does to Flurbiprofen, Omeprazole, Midazolam in Healthy Subjects
A study to investigate the effect of single and repeated oral doses of ACT-539313 on what the body does to flurbiprofen, omeprazole, midazolam in healthy participants.
- Trial name
- NCT05254548
- Testing
- ACT-539313, Flurbiprofen, Omeprazole
- Where
- Germany
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.